Patient and Physician Perspectives on Prostate Cancer Data Presented at ASCO 2025

In this plain language podcast, highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 are discussed. These insights come from the perspective of an expert patient and physician, both of whom have experience and expertise in the field of prostate cancer. This podcast is intended to broaden the reach of complex data and insights from ASCO 2025 to a broader audience, including non-specialists, helping enable better informed treatment decisions between patients and healthcare professionals. The authors begin with a brief summary of the current diagnosis and treatment landscape for patients with prostate cancer, before discussing three topics: personalized therapy for hormone-sensitive prostate cancer; new therapeutics for hormone-resistant prostate cancer; and patient quality of life and supportive care. For hormone-sensitive prostate cancer, biomarker-driven strategies based on genetic and molecular changes in tumor biology and imaging are emerging to help identify which patients may benefit from more targeted treatments. These personalized strategies provide hope to initiate treatment earlier, ultimately preventing disease progression to hormone resistance. For patients who have progressed to difficult-to-treat hormone-resistant prostate cancer, early clinical trials show promise. Novel approaches including radioligands, antibody-drug conjugates, bispecific T cell engagers, and therapy combinations are expanding future treatment options. Finally, mental health screening, educational tools to improve patients' awareness of their disease, and remote health monitoring may help improve the quality of life of patients and their families/caregivers, signposting them to appropriate supportive care. Data presented at ASCO 2025 highlights a shift in the treatment and management of prostate cancer towards a more personalized approach and further amplifies the need to consider individual patient populations. A glossary of abbreviations and terms used in this podcast is provided in the electronic supplementary material. Podcast Audio (MP4 175328 KB).

Authors

Institutions

Publication Details

Journal
Oncology and Therapy
Published
2025-11-26
DOI
https://doi.org/10.1007/s40487-025-00403-w
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Patient and Physician Perspectives on Prostate Cancer Data Presented at ASCO 2025

Thomas C. Hulsey, Pedro Coelho Barata
Oncology and Therapy
Prostate Cancer Diagnosis and Treatment
article

Patient and Physician Perspectives on Prostate Cancer Data Presented at ASCO 2025

Thomas C. Hulsey, Pedro Coelho Barata
article en

Abstract

In this plain language podcast, highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 are discussed. These insights come from the perspective of an expert patient and physician, both of whom have experience and expertise in the field of prostate cancer. This podcast is intended to broaden the reach of complex data and insights from ASCO 2025 to a broader audience, including non-specialists, helping enable better informed treatment decisions between patients and healthcare professionals. The authors begin with a brief summary of the current diagnosis and treatment landscape for patients with prostate cancer, before discussing three topics: personalized therapy for hormone-sensitive prostate cancer; new therapeutics for hormone-resistant prostate cancer; and patient quality of life and supportive care. For hormone-sensitive prostate cancer, biomarker-driven strategies based on genetic and molecular changes in tumor biology and imaging are emerging to help identify which patients may benefit from more targeted treatments. These personalized strategies provide hope to initiate treatment earlier, ultimately preventing disease progression to hormone resistance. For patients who have progressed to difficult-to-treat hormone-resistant prostate cancer, early clinical trials show promise. Novel approaches including radioligands, antibody-drug conjugates, bispecific T cell engagers, and therapy combinations are expanding future treatment options. Finally, mental health screening, educational tools to improve patients' awareness of their disease, and remote health monitoring may help improve the quality of life of patients and their families/caregivers, signposting them to appropriate supportive care. Data presented at ASCO 2025 highlights a shift in the treatment and management of prostate cancer towards a more personalized approach and further amplifies the need to consider individual patient populations. A glossary of abbreviations and terms used in this podcast is provided in the electronic supplementary material. Podcast Audio (MP4 175328 KB).

Oncology and TherapyVol. 14(1)
American Urological Association (US), University Hospitals Seidman Cancer Center (US), The University of Texas Southwestern Medical Center (US)
Openalex Percentile: Top 46%
Prostate Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.